Prognostic value of radiologic extranodal extension in patients with hypopharyngeal cancer treated with primary chemoradiation

Kang-Hsing Fan,Chih-Hua Yeh,Sheng-Ping Hung,Chung-Jan Kang,Shiang-Fu Huang,Kai-Ping Chang,Hung-Ming Wang,Jason Chia-Hsun Hsieh,Chien-Yu Lin,Ann-Joy Cheng,Shu-Hang Ng,Joseph Tung-Chieh Chang
DOI: https://doi.org/10.1016/j.radonc.2020.12.028
IF: 6.901
2021-03-01
Radiotherapy and Oncology
Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Background and purpose</h3><p>We aimed to evaluate the prognostic value of radiologic extranodal extension (rENE) in patients with hypopharyngeal cancer (HPC) treated with primary chemoradiation.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Materials and methods</h3><p>Cancer registry data were reviewed from 2005–2014. Inclusion criteria included HPC, clinical N1-3 disease (AJCC staging system, 7<sup>th</sup> edition), and receiving radiotherapy. Patients with M1 diseaseor with synchronous/metachronous cancer were excluded. Staging images were reviewed by two radiologists. rENE was defined as infiltration of adjacent fat/muscles, irregular nodal surface, or irregular capsular enhancement. Clinical stage, rENE status, and clinical outcome were analyzed.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Results</h3><p>Overall, 355 patients were included. Patients with rENE had lower 3-year overall survival (OS) and recurrence-free survival (RFS) rates. Univariate analysis showed that clinical T4 or N3 stage, overall stage IV, and rENE correlated with OS and RFS. In multivariate analysis, clinical T4 or N3 stage correlated with poor OS, while clinical T4 or N3 stage and rENE were independent predictors of poor RFS. N1/2 without rENE was designated as Group 1, N1/2 with rENE as Group 2, and N3 with/without rENE as Group 3. The 3-year RFS rates in Groups 1, 2, and 3 were 55.8%, 41.0%, and 29.3%, respectively. The 3-year RFS rate in Group 1 was significantly higher than that in the other two groups.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Conclusions</h3><p>rENE is an adverse prognostic factor for survival in patients with HPC treated with primary chemoradiation. It correlated with inferior RFS regardless of N stage. rENE may be used as a criterion for clinical ENE in future staging systems.</p>
oncology,radiology, nuclear medicine & medical imaging
What problem does this paper attempt to address?